Therapeutics News

Biotechnology company Ocugen announced that dosing is complete in the first cohort of its phase 1/2 GARDian clinical trial of OCU410ST, a modifier gene therapy candidate for treatment of Stargardt disease.

Harrow has announced an exclusive out-licensing agreement with Apotex, a major Canadian pharmaceutical company, to market and distribute five of the company’s branded ophthalmic products.

Oculis has completed the first patient visit in its phase 3 OPTIMIZE-2 trial of OCS-01, the company’s preservative-free, once-daily topical formulation of dexamethasone for treating pain and inflammation after cataract surgery.

Skye Bioscience has treated the first patient in its phase 2 study of SBI-100 ophthalmic emulsion, a CB1 agonist delivered as an eye drop to treat patients with elevated IOP, according to a company press release.

After receiving a warning letter from the FDA, the online retailer Amazon removed seven unregulated eye drop products from its website.

The recent FDA warning about 26 potentially contaminated eye drop products, including some marketed under CVS Health, Leader, Rugby, Rite Aid, Target Up&Up and Velocity Pharma, may have caused some confusion among consumers.

Epion Therapeutics has initiated its phase 3 Apricity trials for EpiSmart, a minimally invasive drug-device combination indicated for epithelium-on cross-linking in the treatment of keratoconus.

Dry eye disease is chronic, multifactorial and complex. As a result, management plans have to account for many variables, from underlying conditions to work environments.

NEW ORLEANS — New research in dry eye disease suggests the next few years will bring significant advancements in treatment for patients, according to a speaker at Academy ’23.

The complement component 5 inhibitor avacincaptad pegol may have potential as a treatment to reduce geographic atrophy lesion growth and slow progression of disease, according to a study published in The Lancet.